Not provided
Not provided
Not provided
Not provided
Not provided
Terminated prematurely due to high incidence of postoperative atrial fibrillation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a clinical, randomised, double-blinded study in which patients eligible for aortic valve replacement are enrolled. Patients receive infusion of either levosimendan or placebo 4 hours prior to surgery and until the end of surgery.
Levosimendan or placebo will be infusion for approximately 4 hours prior to aortic valve replacement in patients with severe hypertrophy of the left ventricle and echocardiographic signs of diastolic dysfunction. Outcome measures will be obtained at some of the following:
Outcome measures are comprised of invasive measurements, blood samples, transthoracic echocardiography and transoesophageal echocardiography focusing on measures of systolic and diastolic function of the heart.
Interim analysis will be conducted after 30 included patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| levosimendan | Experimental | infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation |
|
| Placebo | Placebo Comparator | Identical placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| levosimendan | Drug | Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| E/E'(Unitless) | Ration between early transmitral flow (E) and mitral annular tissue velocity(E'). This ratio is an echocardiographic index of diastolic function | 4 hours before operation until 21 hour after operation |
| Measure | Description | Time Frame |
|---|---|---|
| Isovolumetric Relaxation Time (IVRT) (s) | Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function | 4 hours before surgery until 1 hour before operation |
| Ejection Fraction (Per Cent) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Peter Juhl-Olsen, M.D. | Department of Anaesthesiology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anaesthesiology | Århus N | Central Jutland | 8200 | Denmark |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Levosimendan | infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation levosimendan: Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation. |
| FG001 | Placebo | Identical placebo placebo drug: Intravenous infusion, colour identical to levosimendan |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Levosimendan | infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation levosimendan: Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation. |
| BG001 | Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | E/E'(Unitless) | Ration between early transmitral flow (E) and mitral annular tissue velocity(E'). This ratio is an echocardiographic index of diastolic function | Posted | Median | Full Range | Unitless | 4 hours before operation until 21 hour after operation |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Levosimendan | infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation levosimendan: Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Postoperative atrial fibrillation | Cardiac disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Peter Juhl-Olsen | Aarhus University Hospital | +4578451199 | peter.juhl-olsen@ki.au.dk |
Not provided
| ID | Term |
|---|---|
| D017379 | Hypertrophy, Left Ventricular |
| D006333 | Heart Failure |
| D001024 | Aortic Valve Stenosis |
| ID | Term |
|---|---|
| D006332 | Cardiomegaly |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D006984 | Hypertrophy |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077464 | Simendan |
| ID | Term |
|---|---|
| D006835 | Hydrazones |
| D006834 | Hydrazines |
| D009930 | Organic Chemicals |
| D011724 | Pyridazines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo drug | Drug | Intravenous infusion, colour identical to levosimendan |
|
|
Transeosophageal echocardiography: Measure of systolic function
| At start of operation until end of operation, approximately 3 hours |
| Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | 4 hours before operation until 1 hour before operation |
| Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | 4 hours before operation until 1 hours before operation |
| Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | 4 hours before operation until 1 hour before operation |
| Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | 4 hours before operation until 1 hour before operation |
| N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml) | blood sample reflecting stretch of the atrium/ventricle | 4 hours before operation until 4 hours after operation |
| Troponin T (ug/l) | Blood sample expressing damage to the myocytes | 4 hours before operation until 4 hours after operation |
| Lactate (mmol/l) | Arterial sampling of blood lactate | 4 hours before operation until 4 hour after operation |
| Mixed Venous Oxygenation (Per Cent) | Oxygen content (per cent of hemoglobin saturated) of venous blood in pulmonary artery | 4 hours before operation until 4 hour after operation |
| E/A Ratio (Unitless) | TEE ratio between early (E) transmitral flow and late (A) transmitral flow. An index of diastolic function althought not validated properly yet when measured from the oesophagus | At the start of operation until the end of operationon, approximately 3 hours |
| Regional Longitudinal Strain (Unitless) | Transoesophageal echocardiographic (TEE) measure of systolic function. At this time not validated properly against acknowledged indices of systolic function. | At the start of operation until the end of operation, approximately 3 hours |
| Need for Conventional Inotropical Agents | Conventional inotropics are comprised of all inotropics acting primarily through alfa- or beta- stimulation. | From start of operation until 5 days after operation |
| Intravenous Fluid Requirement (l) | Total volume of intravenous fluid required including blood products. | Within 24 hours from start of operation |
| Operation Time (Minutes) | From "knife start" until "knife end", approximately 3 hours |
| Time on Heart-lung Machine (Minutes) | From time of cardioplegia until selfsufficient cardiac action, approximately 1 hour |
| Intubation Time (Minutes) | Total time intubated including time of operation and in the intensive care ward | From intubation until extubation, approximately 6 hours |
| Postoperative Admission Time at Intensive Care Unit (Hours) | Total admission time in the intensive care after operation | From admission to the intensive care unit until discharge from intensive care unit, approximately 24 hours |
| No. of Patients With Adverse Events | Development of Ventricular tachycardia | -4 hours until + 96 hours with respect to start of operation |
| No. of Patients With Adverse Event | Development of atrial flutter/fibrillation | -4 hours until + 96 hours with respect to start of operation |
| No. of Patients With Adverse Event | Need for norepinephrine as an antagonist to the vasodilatatory effect of levosimendan | 4 hours before operaton until 1 hour before operaton |
| No. of Patients With Adverse Event. | Occurence of nausea | 4 hours before operation until 1 hour before operation |
| No. of Patients With Adverse Event | Occurence of headache | 4 hours before operation until approximately 1 hour before operation |
| Regional Longitudinal Strain (Unitless) | Index of systolic function derived from single transthoracic echocardiographic (TTE) projection | 4 hours before until 1 hour before start of operation |
| Ejection Fraction (Per Cent) | TTE: Index of systolic function | 1 hour before until 21 hour after start of operation |
| Ejection Fraction (Per Cent) | TTE: Index of systolic function | 21 hours after operation until 96 hours after start of operation |
| Ejection Fraction (Per Cent) | TTE: Index of systolic function | 96 hours after operation until 6 months after operation |
| Regional Longitudinal Strain (Unitless) | Transoesophageal echocardiographic (TEE) measure of systolic function. At this time not validated properly against acknowledged indices of systolic function. | Froml the end of operation until approx 4 hours after operation |
| E/A Ratio (Unitless) | TEE ratio between early (E) transmitral flow and late (A) transmitral flow. An index of diastolic function althought not validated properly yet when measured from the oesophagus | At the end of operationon until approx 4 hours after operation |
| Left Ventricular Rotation (Degrees) | TTE: Index of both systolic and diastolic function | 96 hour after operation until 6 months after operation |
| Mixed Venous Oxygenation (Per Cent) | Oxygen content (per cent of hemoglobin saturated) of venous blood in pulmonary artery | 4 hours after operation until 21 hours after operation |
| Lactate (mmol/l) | Arterial sampling of blood lactate | 4 hours after operation until 21 hours after operation |
| Troponin T (ug/l) | Blood sample expressing damage to the myocytes | 4 hours after operation until 21 hours after operation |
| Troponin T (ug/l) | Blood sample expressing damage to the myocytes | 21 hours after operation until 96 hours after operation |
| N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml) | blood sample reflecting stretch of the atrium/ventricle | 4 hours after operation until 21 hours after operation |
| N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml) | blood sample reflecting stretch of the atrium/ventricle | 21 hours after operation until 96 hours after operation |
| Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | 1 hour before operation until start of operation |
| Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | Start of operation until the end of operation, approximately 3 hours |
| Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | End of operation until approx 4 hours after operation |
| Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | 4 hours after operation until 21 hours after operation |
| Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | 1 hour before operation until start of operation |
| Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | Start of operation until end of operation, approximately 3 hours |
| Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | End of operation until approx 4 hours after operation |
| Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | 4 hours after operation until 21 hours after operation |
| Regional Longitudinal Strain (Unitless) | Index of systolic function derived from single transthoracic echocardiographic (TTE) projection | 1 hour before start of operation until 21 hours after operation |
| Regional Longitudinal Strain (Unitless) | Index of systolic function derived from single transthoracic echocardiographic (TTE) projection | 21 hours after operation until 96 hours after operation |
| Regional Longitudinal Strain (Unitless) | Index of systolic function derived from single transthoracic echocardiographic (TTE) projection | 96 hours after operation until 6 months after operation |
| Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | 1 hour before operation until start of operation |
| Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | Start of operation until end of operation, approximately 3 hours |
| Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | End of operation until approx 4 hours after operation |
| Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | 4 hours after operation until 21 hours after operation |
| Peak Systolic Velocity (m/s) | Tissue Doppler measure of systolic function | 1 hour before operation until 21 hours after operation |
| Peak Systolic Velocity (m/s) | Tissue Doppler measure of systolic function | 21 hours after operation until 96 hours after operation |
| Peak Systolic Velocity (m/s) | Tissue Doppler measure of systolic function | 96 hours after operation until 6 months after operation |
| Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm) | Transthoracic echocardiographic measure of systolic function | 1 hour before operation until 21 hours after operation |
| Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm) | Transthoracic echocardiographic measure of systolic function | 21 hours after operation until 96 hours after operation |
| Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm) | Transthoracic echocardiographic measure of systolic function | 96 hours after operation until 6 months after operation |
| E/A-ratio (Unitless) | Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function. | 1 hour before operation until 21 hours after operation |
| E/A-ratio (Unitless) | Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function. | 21 hours after operation until 96 hours after operation |
| E/A-ratio (Unitless) | Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function. | 96 hours after operation until 6 months after operation |
| E'/A'-Ratio (Unitless) | Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function. | 1 hour before operation until 21 hours after roperation |
| E'/A'-Ratio (Unitless) | Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function. | 21 hours after operation until 96 hours after operation |
| E'/A'-Ratio (Unitless) | Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function. | 96 hours after operation until 6 months after operation |
| Isovolumetric Relaxation Time (IVRT) (s) | Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function | 1 hour before operation until 21 hours after operation |
| Isovolumetric Relaxation Time (IVRT) (s) | Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function | 21 hours after operation until 96 hours after operation |
| Isovolumetric Relaxation Time (IVRT) (s) | Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function | 96 hours after operation until 6 months after operation |
| Ejection Fraction (Per Cent) | Transeosophageal echocardiography: Measure of systolic function | End of operation until approx. 4 hours after operation |
| Isovolumetric Relaxation Time (IVRT) (s) | Transeosophageal echocardiography: Time from closure of aortic valve to opening of mitral valve. Measure of diastolic function. | End of operation until approx. 4 hours after operation |
| Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | 1 hour before operation until start of operation |
| Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | Start of operation until end of operation, approximately 3 hours |
| Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | End of operation operation until approx. 4 hours after operation |
| Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | 4 hours after operation until 21 hours after operation |
| Inflammatory Parameters | Blood sample values of pro- and antiinflammatory mediators | 4 hours before operation until 21 hours after operation |
| Inflammatory Parameters | Blood sample values of pro- and antiinflammatory mediators | 21 hours after operation until 96 hours after operation |
| E/A-ratio (Transoesophageal) | Transoesophageal echocardiographic measure of diastolic heart function | from start of operation until end of operation, approximately 3 hours |
| E/A-ratio (Transoesophageal) | Transoesophageal echocardiographic measure of diastolic heart function | from end of operation until approximately 4 hours after operation |
| Urine Clearance | Urine analysis. Measure of kidney function. | from start of operation until 24 hours after operation |
Identical placebo placebo drug: Intravenous infusion, colour identical to levosimendan |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Secondary | Isovolumetric Relaxation Time (IVRT) (s) | Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function | Not Posted | 4 hours before surgery until 1 hour before operation | Participants |
| Secondary | Ejection Fraction (Per Cent) | Transeosophageal echocardiography: Measure of systolic function | Not Posted | At start of operation until end of operation, approximately 3 hours | Participants |
| Secondary | Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | Not Posted | 4 hours before operation until 1 hour before operation | Participants |
| Secondary | Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | Not Posted | 4 hours before operation until 1 hours before operation | Participants |
| Secondary | Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | Not Posted | 4 hours before operation until 1 hour before operation | Participants |
| Secondary | Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | Not Posted | 4 hours before operation until 1 hour before operation | Participants |
| Secondary | N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml) | blood sample reflecting stretch of the atrium/ventricle | Not Posted | 4 hours before operation until 4 hours after operation | Participants |
| Secondary | Troponin T (ug/l) | Blood sample expressing damage to the myocytes | Not Posted | 4 hours before operation until 4 hours after operation | Participants |
| Secondary | Lactate (mmol/l) | Arterial sampling of blood lactate | Not Posted | 4 hours before operation until 4 hour after operation | Participants |
| Secondary | Mixed Venous Oxygenation (Per Cent) | Oxygen content (per cent of hemoglobin saturated) of venous blood in pulmonary artery | Not Posted | 4 hours before operation until 4 hour after operation | Participants |
| Secondary | E/A Ratio (Unitless) | TEE ratio between early (E) transmitral flow and late (A) transmitral flow. An index of diastolic function althought not validated properly yet when measured from the oesophagus | Not Posted | At the start of operation until the end of operationon, approximately 3 hours | Participants |
| Secondary | Regional Longitudinal Strain (Unitless) | Transoesophageal echocardiographic (TEE) measure of systolic function. At this time not validated properly against acknowledged indices of systolic function. | Not Posted | At the start of operation until the end of operation, approximately 3 hours | Participants |
| Secondary | Need for Conventional Inotropical Agents | Conventional inotropics are comprised of all inotropics acting primarily through alfa- or beta- stimulation. | Not Posted | From start of operation until 5 days after operation | Participants |
| Secondary | Intravenous Fluid Requirement (l) | Total volume of intravenous fluid required including blood products. | Not Posted | Within 24 hours from start of operation | Participants |
| Secondary | Operation Time (Minutes) | Not Posted | From "knife start" until "knife end", approximately 3 hours | Participants |
| Secondary | Time on Heart-lung Machine (Minutes) | Not Posted | From time of cardioplegia until selfsufficient cardiac action, approximately 1 hour | Participants |
| Secondary | Intubation Time (Minutes) | Total time intubated including time of operation and in the intensive care ward | Not Posted | From intubation until extubation, approximately 6 hours | Participants |
| Secondary | Postoperative Admission Time at Intensive Care Unit (Hours) | Total admission time in the intensive care after operation | Not Posted | From admission to the intensive care unit until discharge from intensive care unit, approximately 24 hours | Participants |
| Secondary | No. of Patients With Adverse Events | Development of Ventricular tachycardia | Not Posted | -4 hours until + 96 hours with respect to start of operation | Participants |
| Secondary | No. of Patients With Adverse Event | Development of atrial flutter/fibrillation | Not Posted | -4 hours until + 96 hours with respect to start of operation | Participants |
| Secondary | No. of Patients With Adverse Event | Need for norepinephrine as an antagonist to the vasodilatatory effect of levosimendan | Not Posted | 4 hours before operaton until 1 hour before operaton | Participants |
| Secondary | No. of Patients With Adverse Event. | Occurence of nausea | Not Posted | 4 hours before operation until 1 hour before operation | Participants |
| Secondary | No. of Patients With Adverse Event | Occurence of headache | Not Posted | 4 hours before operation until approximately 1 hour before operation | Participants |
| Secondary | Regional Longitudinal Strain (Unitless) | Index of systolic function derived from single transthoracic echocardiographic (TTE) projection | Not Posted | 4 hours before until 1 hour before start of operation | Participants |
| Secondary | Ejection Fraction (Per Cent) | TTE: Index of systolic function | Not Posted | 1 hour before until 21 hour after start of operation | Participants |
| Secondary | Ejection Fraction (Per Cent) | TTE: Index of systolic function | Not Posted | 21 hours after operation until 96 hours after start of operation | Participants |
| Secondary | Ejection Fraction (Per Cent) | TTE: Index of systolic function | Not Posted | 96 hours after operation until 6 months after operation | Participants |
| Secondary | Regional Longitudinal Strain (Unitless) | Transoesophageal echocardiographic (TEE) measure of systolic function. At this time not validated properly against acknowledged indices of systolic function. | Not Posted | Froml the end of operation until approx 4 hours after operation | Participants |
| Secondary | E/A Ratio (Unitless) | TEE ratio between early (E) transmitral flow and late (A) transmitral flow. An index of diastolic function althought not validated properly yet when measured from the oesophagus | Not Posted | At the end of operationon until approx 4 hours after operation | Participants |
| Secondary | Left Ventricular Rotation (Degrees) | TTE: Index of both systolic and diastolic function | Not Posted | 96 hour after operation until 6 months after operation | Participants |
| Secondary | Mixed Venous Oxygenation (Per Cent) | Oxygen content (per cent of hemoglobin saturated) of venous blood in pulmonary artery | Not Posted | 4 hours after operation until 21 hours after operation | Participants |
| Secondary | Lactate (mmol/l) | Arterial sampling of blood lactate | Not Posted | 4 hours after operation until 21 hours after operation | Participants |
| Secondary | Troponin T (ug/l) | Blood sample expressing damage to the myocytes | Not Posted | 4 hours after operation until 21 hours after operation | Participants |
| Secondary | Troponin T (ug/l) | Blood sample expressing damage to the myocytes | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml) | blood sample reflecting stretch of the atrium/ventricle | Not Posted | 4 hours after operation until 21 hours after operation | Participants |
| Secondary | N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml) | blood sample reflecting stretch of the atrium/ventricle | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | Not Posted | 1 hour before operation until start of operation | Participants |
| Secondary | Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | Not Posted | Start of operation until the end of operation, approximately 3 hours | Participants |
| Secondary | Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | Not Posted | End of operation until approx 4 hours after operation | Participants |
| Secondary | Systemic Arterial Pressure (mmHg) | Invasive measurements of arterial mean pressure | Not Posted | 4 hours after operation until 21 hours after operation | Participants |
| Secondary | Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | Not Posted | 1 hour before operation until start of operation | Participants |
| Secondary | Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | Not Posted | Start of operation until end of operation, approximately 3 hours | Participants |
| Secondary | Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | Not Posted | End of operation until approx 4 hours after operation | Participants |
| Secondary | Pulmonary Artery Pressures (mmHg) | Invasive measurement of mean pressure in the pulmonary artery | Not Posted | 4 hours after operation until 21 hours after operation | Participants |
| Secondary | Regional Longitudinal Strain (Unitless) | Index of systolic function derived from single transthoracic echocardiographic (TTE) projection | Not Posted | 1 hour before start of operation until 21 hours after operation | Participants |
| Secondary | Regional Longitudinal Strain (Unitless) | Index of systolic function derived from single transthoracic echocardiographic (TTE) projection | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | Regional Longitudinal Strain (Unitless) | Index of systolic function derived from single transthoracic echocardiographic (TTE) projection | Not Posted | 96 hours after operation until 6 months after operation | Participants |
| Secondary | Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | Not Posted | 1 hour before operation until start of operation | Participants |
| Secondary | Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | Not Posted | Start of operation until end of operation, approximately 3 hours | Participants |
| Secondary | Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | Not Posted | End of operation until approx 4 hours after operation | Participants |
| Secondary | Central Venous Pressure (mmHg) | Invasive measurement of pressure in the vena cava | Not Posted | 4 hours after operation until 21 hours after operation | Participants |
| Secondary | Peak Systolic Velocity (m/s) | Tissue Doppler measure of systolic function | Not Posted | 1 hour before operation until 21 hours after operation | Participants |
| Secondary | Peak Systolic Velocity (m/s) | Tissue Doppler measure of systolic function | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | Peak Systolic Velocity (m/s) | Tissue Doppler measure of systolic function | Not Posted | 96 hours after operation until 6 months after operation | Participants |
| Secondary | Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm) | Transthoracic echocardiographic measure of systolic function | Not Posted | 1 hour before operation until 21 hours after operation | Participants |
| Secondary | Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm) | Transthoracic echocardiographic measure of systolic function | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm) | Transthoracic echocardiographic measure of systolic function | Not Posted | 96 hours after operation until 6 months after operation | Participants |
| Secondary | E/A-ratio (Unitless) | Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function. | Not Posted | 1 hour before operation until 21 hours after operation | Participants |
| Secondary | E/A-ratio (Unitless) | Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function. | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | E/A-ratio (Unitless) | Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function. | Not Posted | 96 hours after operation until 6 months after operation | Participants |
| Secondary | E'/A'-Ratio (Unitless) | Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function. | Not Posted | 1 hour before operation until 21 hours after roperation | Participants |
| Secondary | E'/A'-Ratio (Unitless) | Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function. | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | E'/A'-Ratio (Unitless) | Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function. | Not Posted | 96 hours after operation until 6 months after operation | Participants |
| Secondary | Isovolumetric Relaxation Time (IVRT) (s) | Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function | Not Posted | 1 hour before operation until 21 hours after operation | Participants |
| Secondary | Isovolumetric Relaxation Time (IVRT) (s) | Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | Isovolumetric Relaxation Time (IVRT) (s) | Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function | Not Posted | 96 hours after operation until 6 months after operation | Participants |
| Secondary | Ejection Fraction (Per Cent) | Transeosophageal echocardiography: Measure of systolic function | Not Posted | End of operation until approx. 4 hours after operation | Participants |
| Secondary | Isovolumetric Relaxation Time (IVRT) (s) | Transeosophageal echocardiography: Time from closure of aortic valve to opening of mitral valve. Measure of diastolic function. | Not Posted | End of operation until approx. 4 hours after operation | Participants |
| Secondary | Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | Not Posted | 1 hour before operation until start of operation | Participants |
| Secondary | Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | Not Posted | Start of operation until end of operation, approximately 3 hours | Participants |
| Secondary | Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | Not Posted | End of operation operation until approx. 4 hours after operation | Participants |
| Secondary | Cardiac Index (l/Min/m2) | Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula) | Not Posted | 4 hours after operation until 21 hours after operation | Participants |
| Secondary | Inflammatory Parameters | Blood sample values of pro- and antiinflammatory mediators | Not Posted | 4 hours before operation until 21 hours after operation | Participants |
| Secondary | Inflammatory Parameters | Blood sample values of pro- and antiinflammatory mediators | Not Posted | 21 hours after operation until 96 hours after operation | Participants |
| Secondary | E/A-ratio (Transoesophageal) | Transoesophageal echocardiographic measure of diastolic heart function | Not Posted | from start of operation until end of operation, approximately 3 hours | Participants |
| Secondary | E/A-ratio (Transoesophageal) | Transoesophageal echocardiographic measure of diastolic heart function | Not Posted | from end of operation until approximately 4 hours after operation | Participants |
| Secondary | Urine Clearance | Urine analysis. Measure of kidney function. | Not Posted | from start of operation until 24 hours after operation | Participants |
| 0 |
| 10 |
| 9 |
| 10 |
| EG001 | Placebo | Identical placebo placebo drug: Intravenous infusion, colour identical to levosimendan | 0 | 10 | 6 | 10 |
Not provided
Not provided
Not provided
| D020763 |
| Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |
| D014694 | Ventricular Outflow Obstruction |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |